SynthesisJournal of endocrinological investigation2026
Radioactive iodine and male reproductive health in thyroid cancer survivors: evidence of delayed gonadal dysfunction.
Synthesis in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systematic adolescent-centered supportive care program is associated with improved psychological status, treatment adherence, and social adaptation in adolescents with thyroid cancer undergoing radioiodine-131 therapy: a retrospective before-after cohort study with historical controls.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDifferentiated thyroid carcinoma (DTC) incidence is rising globally, with a higher prevalence in women. Male patients often present with more aggressive disease, leading to more frequent use of radioactive iodine (RAI) therapy. While the gonadotoxic effects of RAI in females have been studied, its impact on male reproductive health remains unclear. This study is aimed to assess the effects of RAI therapy on gonadal function in men with DTC, focusing primarily on follicle-stimulating hormone (FSH) serum levels as a biomarker of testicular function.
methodsWe analyzed studies reporting FSH levels before and after RAI administration in male DTC patients. The primary outcome was the change in FSH levels over time, with secondary outcomes including luteinizing hormone (LH) levels and semen parameters.
resultsSeven studies comprising 460 men met inclusion criteria. FSH levels significantly increased 12 months post-RAI (mean difference6.56 IU/L; p < 0.001), but not at 3 or 6 months. Meta-regression revealed that FSH elevation was positively associated with patient age and RAI dosage. No significant changes were observed in LH levels or standard semen parameters. Despite high heterogeneity (I²=99%), sensitivity analyses confirmed the findings.
conclusionRAI therapy in male DTC patients is associated with delayed and dose-dependent increases in FSH, suggesting a potential subclinical impact on testicular function, particularly spermatogenesis. Standard semen parameters remain stable initially, possibly due to compensatory mechanisms. Powerful, prospective studies are needed to assess long-term reproductive outcomes and explore qualitative sperm alterations, including DNA integrity, to better inform fertility counseling in male DTC patients undergoing RAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.